Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purified fusion proteins induced serotype-specific neutralizing antibodies without cross-reaction against other serotypes and arboviruses after mouse immunization. hydrophobin-fused domain III of dengue envelope protein could be a promising strategy for easy and low-cost production of components of a tetravalent sub-unit vaccine against dengue.
|
31828570 |
2020 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
A star-shaped DNA architecture, carrying five molecular beacon-like motifs, was constructed to display ten dengue envelope protein domain III (ED3)-targeting aptamers into a two-dimensional pattern precisely matching the spatial arrangement of ED3 clusters on the dengue (DENV) viral surface.
|
31767992 |
2020 |
Virus Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) results in robust blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV).
|
31787208 |
2020 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attachment of envelope glycoprotein gp120 to the host cell receptor CD4 is the first step during the human immunodeficiency virus-1 (HIV-1) entry into the host cells that makes it a promising target for drug design.
|
31792886 |
2020 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) results in robust blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV).
|
31787208 |
2020 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The human immunodeficiency virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of HIV-associated neurocognitive disorder (HAND).
|
31320730 |
2020 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, the consensus dengue virus envelope protein domain III fused to hydrophobin I of Trichoderma reesei was expressed in Pichia pastoris cultures and an in situ product removal by an ATPS using a non-ionic detergent, (Triton X-114) was performed.
|
30240632 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we focused on the Dengue viral envelope protein (E); computational analyses ranging from extensive Molecular Dynamics (MD) simulations and energy-decomposition-based prediction of potentially immunoreactive regions identified putative epitope sequences.
|
31003530 |
2019 |
Dengue Fever
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, two highly conserved regions of dengue envelope protein were identified and an scFv was constructed against it.
|
30629625 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated four types of recombinant envelope protein domain III (DV-rED III) derived from four dengue virus (DENV) serotypes for diagnostic potential in detecting IgM in acute phase (mainly 2-3 days after onset of fever).
|
31311082 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
The virtual approach was based on generating different docking cycles of tetra, penta, hexa, and heptapeptide libraries by maximizing the discrimination between the amino acid motif in the ZIKV and dengue virus (DENV) envelope protein glycosylation site.
|
31533374 |
2019 |
Dengue Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Zika (ZIKV) and dengue (DENV) virus infections elicit a robust but cross-reactive antibody response against the viral envelope protein, while antibody responses against non-structural proteins (NS) are more virus specific.
|
30902827 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have developed a fully human, second-generation CAR directed against the envelope protein of hepatitis B virus on the surface of infected cells (S-CAR).
|
30852138 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure-Guided Approach to Identify Potential Inhibitors of Large Envelope Protein to Prevent Hepatitis B Virus Infection.
|
31772697 |
2019 |
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we show that a viral membrane protein, the duck hepatitis B virus (DHBV) large envelope protein (DHBs L), produced by WG-CFPS, is phosphorylated upon translation at the same sites as DHBs L produced during DHBV infection of primary hepatocytes.
|
31850370 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the aa 158 sequence determined attachment of the HBV envelope protein to the host cell, demonstrating the mechanism whereby HBV infection would create positive selection at this NTCP residue.
|
30541857 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we modified synthetic lipid-based nanoparticles with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target the sodium-taurocholate cotransporting polypeptide (NTCP; <i>SLC10A1</i>) on the sinusoidal membrane of hepatocytes.
|
31333191 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion.
|
30415392 |
2019 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first report on the mechanisms of HBV envelope protein transport among the organelles, and the results provide important insights into the therapeutic control of HBV infection.
|
31118260 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics.
|
30602023 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we constructed genetic vaccines based on novel recombinant adeno‑associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b.
|
30569131 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers.
|
29443378 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, statistically significant associations were found between HCV quasispecies diversity, selective pressure exerted on the HCV E2 envelope protein, and neutralizing activity of maternal immunoglobulins.
|
30365007 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Assembly of infectious hepatitis C virus (HCV) particles is known to involve host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies now suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2.
|
30880226 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
NS2 also promotes HCV particle assembly by recruiting envelope protein 2 (E2) to the virus assembly sites located at the detergent-resistant membranes (DRM).
|
31597774 |
2019 |